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Available online 29 October 2016Wnt signaling plays a central role in tumor initiation and tumor progression. Mutations inWnt pathway compo-
nents, such as the tumor suppressor APC, lead to malignant transformation. While previous studies focused on
Wnt-related changes in cancer cells, the impact of aberrant Wnt signaling on the tumor microenvironment is
only beginning to emerge. In order to investigate the role of increased Wnt secretion on tumor growth and the
microenvironment, we generated a novel germ cell tumor model by overexpressing the Wnt secretion factor
Evi/Wls in mouse embryonic stem cells. Evi-overexpressing teratoma were characterized by enhanced tumor
growth in supporting a tumor-promoting role ofWnt secretion. Interestingly, enhanced Evi expression correlated
with impaired immune cell recruitment. Speciﬁcally, T- and B-cell inﬁltrationwas reduced in Evi-overexpressing
teratomas, which was independent of teratoma size and differentiation. Our study suggests that Wnt secretion
impairs immunosurveillance. Since immune cell inﬁltration has been shown to have prognostic value, the levels
of secreted Wnt activity might impact the efﬁciency of cancer immunotherapy.
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Cells of the tumor microenvironment exert context-dependent pro-
and anti-tumorigenic functions (de Visser et al., 2006; Hanahan and
Weinberg, 2011). Tumor-inﬁltrating leukocytes execute critical func-
tionswithin the complex interactions of tumor cells with theirmicroen-
vironment. Immunosurveillance mechanisms within the tumor stroma
enable the immune system to recognize transformed cells in order to
initiate mechanisms of their inhibition or elimination (Dunn et al.,
2002; Dunn et al., 2004; Schreiber et al., 2011). During
immunosurveillance, cells of the innate and the adaptive immune sys-
tem cooperate to prevent the growth of neoplastic tissues (Mittal et
al., 2014). The cascade starts with an inﬂammatory signal produced by
the tumor cells, which leads to the recruitment of natural killer (NK)
cells, macrophages and dendritic cells (DC), followed by T-cell inﬁltra-
tion and activation of their cytotoxic function.
Recent meta-analyses of solid tumors have shown that the CD3+ T
cells inﬁltration correlates with good prognosis (Gooden et al., 2011;
Hwang et al., 2012; Mittal et al., 2014; Nakano et al., 2001; Sato et al.,
2005; Sharma et al., 2007). However, it is an open question why some
tumors are highly inﬁltrated by T cells and others are not. Recent reports
suggest that Wnt/β-catenin signaling in melanoma impairs thees, Faculty of Biotechnology and
y.
wt.de (I. Augustin).
earch Center, Heidelberg, Germany.antitumor immune response and thereby supports cancer cell-induced
immunosuppression (Spranger et al., 2015; Yaguchi et al., 2012). Thus,
the better understanding of the involved signaling mechanisms may
provide insights into the immune escape mechanisms of tumor cells.
The highly conserved transmembrane molecule Evi/Wls/Gpr177 is
an essential component of the Wnt secretion machinery (Banziger et
al., 2006; Bartscherer et al., 2006). It is required for the exocytosis of
Wnt proteins acting as a Wnt cargo receptor by shuttling between the
Golgi, the plasma membrane and endosomal compartments
(Bartscherer and Boutros, 2008). Evi is a single-gene family in verte-
brates (Jin et al., 2010; Port and Basler, 2010). Thus, it has been assumed
that Evi is involved in the secretion of allWntproteins. Correspondingly,
Evi depletion globally affects Wnt signaling with consequences for ca-
nonical as well as non-canonical Wnt signaling. This, in turn, can be
exploited as a unique experimental tool to modulate Wnt signaling
through the regulation of Wnt ligand secretion. Genetic inactivation of
Evi in mice results in embryonic lethality due to disruption of axial pat-
terning with missing mesoderm and primitive streak formation
(Augustin et al., 2013; Fu et al., 2009).
Embryonic stem cells (ESCs) are widely used to study early differen-
tiation processes (Posfai et al., 2014). They also hold promise for thera-
peutic approaches in the ﬁeld of regenerative medicine (Dressel, 2011;
Dressel et al., 2008; Song et al., 2015; Tang and Drukker, 2011). Yet, im-
mune rejection resulting from mismatch histocompatibility is a poten-
tial limitation of stem cell-based therapies, restricting the rate of
successful transplantation (Zhao et al., 2011; Jin et al., 2015). Moreover,Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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undifferentiated ESCs give rise to teratomas, which resemble benign tu-
mors that consist of tissues derived from the three embryonic germ
layers (Przyborski, 2005; Lee et al., 2013). Accordingly, teratoma forma-
tion assays need to be performed to conﬁrm ESC pluripotency in a com-
plex in vivo environment. Teratoma assays are also pursued as a model
to investigate the crosstalk between ESCs and stromal cells (Przyborski,
2005; Dressel, 2011). We previously generated Evi-overexpressing
mouse ESCs (Evi-GOF) via knockin into the ROSA26 locus to study
Wnt secretion in ESCs (Augustin et al., 2012). Evi-GOF ESCs showed en-
hanced Wnt activity, which had no effect on ESC pluripotency and via-
bility. Teratoma experiments with Evi-GOF ESCs conﬁrmed
pluripotency characterized bymeso-, endo- and ectodermal lineage dif-
ferentiation although Evi-GOF ESCs revealed a preference for cardio-
myocyte differentiation. Based on these ﬁndings, the present study
was aimed at investigating Evi during teratoma formation in order to
clarify the role of Wnt secretion in teratoma–stroma interactions in a
deﬁnite genetic setting.2. Results
2.1. Evi overexpression leads to larger teratomas in syngeneicmice and pro-
motes cardiogenic differentiation
ESCs express a repertoire of Wnt ligands, which activate canonical
and non-canonical Wnt signaling cascades. As a cargo-receptor, Evi
acts as a gatekeeper to release or block Wnt secretion. Increased levels
of the cargo-receptor have been detected in different tumor entities
(Augustin et al., 2012; Voloshanenko et al., 2013; Lu et al., 2015). Ac-
cordingly, Evi overexpression (Evi-GOF) leads to a global increase of se-
cretedWnt proteins and represent a model of enhancedWnt signaling.
Evi-GOF ESCs ectopically express Evi-YFP, which is localized to the se-
cretory pathway (Fig. 1A). FACS-based analysis of ESCs conﬁrmed the
surface expression of Evi-YFP, indicating proper cellular trafﬁcking of
Evi-YFP (Fig. 1B). Western blots of ESC supernatants showed increased
Wnt5a/5b secretion of Evi-GOF ESCs, which was abolished in the pres-
ence of LGK947 (Fig. 1C). Previous results showed an increasedWnt-re-
porter activity of Evi-GOF ESCs (Augustin et al., 2012). Accordingly,
LRP6, the co-receptor of Frizzled, revealed higher phosphorylation in
Evi-GOF ESCs compared to control cells, which was prevented after
LGK947 treatment (Fig. 1D). Likewise, expression of the Wnt target
gene Axin2was increased (Fig. 1E).
Wnt signaling has been shown to support ESC maintenance. There-
fore, we investigated the expression of the pluripotency markers Oct4,
Nanog, Sox2, Rex1 as well as Epi-stem cellmarker Claudin1 and early dif-
ferentiation markers CD133 and Fgf5 (Fig. 1F, G). Enhanced Wnt secre-
tion resulted in no signiﬁcant changes in their gene expression.
Similarly, protein expression of Nanog, SSEA1 and Oct4 was unchanged
based on FACS analysis indicating no major alterations in the
pluripotency network of Evi-GOF ESCs. Moreover, enhancedWnt secre-
tion had no effect on the viability and growth of cultured Evi-GOF ESCs
(Fig. 1H). Similar growth curves were observed in the presence of low
serum concentrations (5%) or in the absence of LIF (data not shown).
Subcutaneous injection of Evi GOF and control ESCs in syngenic re-
cipients (129P2/OlaHsd) were performed to generate teratomas and
analyze the differentiation potential if ESC in vivo. Monitoring of
tumor growth over time revealed larger tumors in Evi GOF ESCs (Fig.
2A). Evi-YFP expression was detected in Evi-GOF teratoma sections
(Fig. 2B). Labeled cells showed prominent perinuclear and surface stain-
ing and were clearly distinguishable from unlabeled host-derived stro-
mal cells (Fig. 2B). Histological analysis of teratomas was performed to
assess thedifferentiation potential of the injected ESCs. H&E stained sec-
tions showed characteristic structure of endo-, meso- and ectodermal
differentiation (Fig. 2C). Proliferation of tumor cells was not altered as
evidenced by EdU-incorporation experiments (Fig. 2D). Activecaspase-3 labeling showed reduced apoptosis rate in Evi-GOF terato-
mas. However, it was not signiﬁcant. (Fig. 2E).
In order to understand the differences between in vitro and in vivo
growth, we performed expression proﬁling of teratomas from Evi-GOF
and control ESCs. RNA from teratomas was isolated and analyzed by
array-based expression proﬁles to study cellular and molecular mecha-
nisms underlying Evi-GOF teratoma development. A set of 18 geneswas
signiﬁcantly upregulated and 123 genes were downregulated in Evi-
GOF teratomas (absolute value of log2 fold change N1; adj. p-
value b 0.05) (Fig. 3A). Tissue-related expression analysis of the upreg-
ulated genes based on TiGER proﬁles (http://bioinfo.wilmer.jhu.edu/
tiger/) showed that 61% of the genes had amuscle and heart association,
whereas 39% of the genes were ubiquitously expressed or had other tis-
sue preferences, supporting the concept that Evi-GOF ESCs reinforced
mesodermal differentiation to result in enhanced muscle development
(Fig. 3B). Similar results were reported after Wnt1 overexpression
(Weisel et al., 2010) or sustained treatment of ESCs with Wnt3a or
GSK-inhibitor (Bakre et al., 2007). The list of upregulated genes related
to muscle and heart development is summarized in Fig. 3C.
2.2. Reduced expression of immune-modulatory genes in Evi-overexpress-
ing teratomas
Among the downregulated genes, the highest enrichment was ob-
served in genes categorized as immunity and defense (43% of the down-
regulated genes) as well as signal transduction (30% of the
downregulated genes) (Fig. 3D). Similarly, genes involved in T- and B-
cell-mediated immunity, as well as innate immunity were differentially
expressed suggesting an altered immune response (Fig. 3D). Among
others, the genes coding for three CD3 chains (CD3γ, CD3δ, CD3ε) –
part of the TCR-CD3 complex – were downregulated about 3-fold (Fig.
3E). The CD79b antigen, part of the B lymphocyte antigen receptor,
was also downregulated (Fig. 2E). Next, we studied if surface markers
involved in T cell activation and survival were differentially expressed
in Evi-GOF and control teratomas. The B7 family members CD80 (B7–
1) and CD86 (B7–2) work in tandem to activate T cells via binding to
CD28 co-receptor. Following activation, the inhibitory receptor CTLA-4
is induced in T cells, which compete with CD28 for CD80 and CD86 li-
gands and provided an inhibitory signal to stop T cell activation. In con-
trast to CD86, CD80 expression was reduced in Evi-GOF teratomas
suggesting an imbalance in T cell activation in Evi-GOF tumors com-
pared to controls (Fig. 3F). However, CTLA-4, PD-L1 and MHC class II
and I markers were not signiﬁcantly changed, suggesting that no
major differences regarding tumor recognition by the immune system
were apparent (Fig. 3F). Imunohistochemical analysis against MHC
class II revealed heterogeneous but similar staining pattern (Fig. 3G).
This result might be due to the fact, that embryonic stem cells are
non-cancer cells but develop benign teratomas composed of cells re-
sembling normal derivatives and therefore, other than tumor cells, do
not use mechanisms to become less immunogenic. Further detailed
quantitative analysis on marker gene expression would be necessary
to conﬁrm this conclusion.
2.3. Evi overexpression affects teratoma-immune-cell crosstalk
Expression studies showed that Evi-overexpressing ESCs favored a
cardiomyocyte gene expression proﬁle, and that immune regulatory
genes were downregulated. Enhanced muscle differentiation might be
associated with an altered immune response indicating that the cardio-
myocyte lineage itself and not theWnt overexpressing teratoma cells in
general is linked to reduced immune cell crosstalk. Therefore, we com-
pared the expression of the cardiomyocyte marker troponin C type 1
(Tnnc1) and the skeletal muscle marker myosin heavy chain 8 (Myh8)
as a surrogatemarker of cardiomyocyte differentiation,with the expres-
sion pattern of the immune cell markers CD3 (T cells) and CD19 (B
cells). The correlation (R2) between Myh8 and Tnnc1 with CD3 or
Fig. 1. Evi-GOF ESCs have enhancedWnt signaling activity with unaltered cell viability. (A) Evi-GOF and control ESC colony. Evi-YFP expressionwas localized to the secretory pathway and
the plasmamembrane. DAPI stained the nucleus. (B) FACS analysis of unpermeabilized and permeabelized ESCswith an antibody against Evi or GFP conﬁrmed Evi-YFP expression on the
cell surface. (C)Western blot of control and Evi-GOF ESC culture supernatants generated in the presents or absence of LGK974were incubatedwith antibodies againstWnt5a/b and Hsc70
for loading control (D)Western blot of control and Evi-GOF ESC lysates incubatedwith antibodies against YFP, phospho-LRP6 and LRP6 dependent on LGK974 treatment. β-actinwas used
as a loading control. (E, F) RT-PCR analysis of control and Evi-GOF ESCs for indicated genes 48 h after seeding. (G) FACS analysis of Evi-GOF and control cellswith indicated antibodies. Grey
area represents unstained cells. (H) Relative viability of Evi-GOF and control cells over time. ESCs were depleted of MEFs and incubated in the presence of LIF-containing medium. Data
represent mean ± SD of 3 independent experiments. Similar results were obtained with an independent ESC line.
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temmarkers was not affected by altered teratoma differentiation in the
Evi-GOF tumors (Fig. S1A).
As shown above, Evi-GOF teratomawere larger than control tumors
(Fig. 2B). We therefore analyzed whether the inﬁltration of immune
cells in general was dependent on teratoma size. FACS-based analysis
of control teratoma tissue was performed after 27 days of growth. We
analyzed the percentage of CD45+ and CD3+populations from total ter-
atoma cells harvested from tumors of various sizes ranging from 0.4mg
to 0.9 mg (Fig. S1B) and found no signiﬁcant correlation between the
number of CD45+ and CD3+ cells and tumor weight.
Given that Evi-GOF teratomas showed predominately down-regula-
tion of genes, whichwere functionally related to immunity and defense,we hypothesized that Evi expression may affect immune cell inﬁltra-
tion. Therefore, we FACS-proﬁled the leukocytes that had inﬁltrated
the teratomas. We found that the number of CD45+ cells was 2-fold
higher in the control teratomas compared to Evi-GOF teratomas (Fig.
4A). The data indicates that constitutive overexpression of Evi in ESCs
suppressed teratoma immune cell inﬁltration.
To further investigate the frequency of leukocyte subpopulations in
Evi-GOF and control teratomas, we performed FACS proﬁling
distinguishing the inﬁltrated cell numbers of lymphocytes and myeloid
populations. CD45+ subpopulation analysis revealed about 50% reduc-
tion in CD3+ T cells as well as CD19+ B cells, whereas F4/80+, Gr1−
macrophages, Gr1+, CD11b+ granulocytes and CD49b+, CD3− NK
cells were not signiﬁcantly altered (Fig. 4A). The ratio of T- to B cells
Fig. 2. Teratomas from Evi-overexpression and control ESC. (A) Tumor size after 27 days of teratoma growth in 129P2/OlaHsdmice (control n=14, Evi-GOF n=10) Data represents SEM
of 2 independent experiments (upper panel). Representative pictures of Evi-GOF and control teratomas (scale bar 1 cm) (lower panel). (B) Representative section of Evi-GOF teratomas
stainedwith an anti-GFP antibody. (C) Teratoma sections from Evi-GOF and control tumors stained with H&E (scale bar 100 μm). (E) Analysis of EdU-labeled cells of control and Evi-GOF
tumors. (D) Analysis of active caspase3(+) cells in Evi-GOF and control teratomas. Data represent mean ± SD of 3 independent experiments, 2 independent clones per genotype were
tested. ★p b 0.05.
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shown), indicating that both T-and B cells were affected. Immunohisto-
chemical analysis of CD3+ cells conﬁrmed the reduced T-cell recruit-
ment in Evi-GOF teratomas (Fig. S2A).
If the tumor-promoting role ofWnt secretion relied on reduced lym-
phocyte inﬁltration, persistance and/or impaired T cell activation, the
growth advantage of Evi-GOF teratomas grown in immune-compro-
mised Nod/SCID mice, which are deﬁcient in mature T and B cells,
should be lost. Indeed, in Nod/SCID mice, tumor sizes (and lymphoid
immune inﬁltration) of Evi-GOF- and control tumors were comparable,
supporting the hypothesis that exacerbatedWnt secretion impaired the
antitumor immune surveillance of the adaptive immune system (Fig.
4B, C), rather than conferring an intrinsic growth advantage. Subse-
quent analysis of CD4+ and CD8+ T cell subsets revealed similar distri-
bution in Evi-GOF and control tumors (Fig. 4D). The CD4+/CD8a+ ratio
was also indistinguishable in both teratoma types (Fig. S2B). Further
analysis of T cells regarding CD4+ effector memory (TEM: CD44hi,
CD62L−), central memory (TCM: CD44hi, CD62L+), and naïve (TN:
CD44−, CD62L+) subpopulations showed no changes in Evi-GOF terato-
mas compared to controls (Fig. 4E). The proﬁling of CD8+ cells revealed
no signiﬁcant alterations in TEM and TCM subpopulations whereas the
fraction of naïve cells in Evi-GOF teratomas was about 50% reduced
(Fig. 4F). Similarly, the activated T cell populations expressing CD69+
were not altered in Evi-GOF teratomas (Fig. S2C). The ability of CD4+
T cells to exert effector functions depends on their differentiation.Wnt/β-catenin signaling regulates lineage fate decisions in both the
thymus and in peripheral lymphoid tissue and it enhances the survival
of regulatory T (Treg) cells (Ding et al., 2008) (Yu et al., 2010) (Notani
et al., 2010). Interestingly, the fraction of CD4+, CD25+, FoxP3+ regula-
tory T cells was signiﬁcantly increased in Evi-GOF teratomas (Fig. 4G).
Similarly, the frequency of IL17-producing CD4+Th17 cells was elevat-
ed in Evi-GOF teratomas supporting the idea that Wnt signaling en-
hanced Th17 differentiation (Fig. 4H) (Ma et al., 2011; Dai et al., 2016;
Muranski et al., 2011). Next, we asked for extracellular factors responsi-
ble for Th17 differentiation. Stimulating naïve T cells with TGF-β and IL6
is sufﬁcient to induce IL17 producing cells (Ma et al., 2011). Q-PCR anal-
ysis of IL6 expression in Evi-GOF and control tumors revealed almost 2-
fold upregulation of IL6 in Evi-GOF teratomas suggesting that IL6-Stat3
signaling cascade is more pronounced in Evi-GOF teratomas and might
contribute to enhanced Th17 differentiation.
In order to investigate the correlation of Evi expression and leuco-
cytemarkers in tumor patient biopsies we performed expression analy-
sis of cancer proﬁles. Using the R2 -Genomics Analysis andVisualization
Platform we analyzed the co-expression of Evi and leucocyte markers
(CD45, CD3ε, CD3δ, CD4, CD8a, F4/80, CD19) in colon cancer patient co-
horts (Tumor Colon Sieber 315 Mas5.0-u133p2, Fig. S3A). Our analysis
revealed that tumor samples with high Evi expression showed low ex-
pression of leukocyte markers indicating that Wnt signaling interferes
with the tumor-immune crosstalk in mouse and human tumor tissues.
Similar results were obtained with a second colon cancer database
Fig. 3. Expression proﬁling of Evi-GOF teratomas. (A) Scatter plot showing differentially regulated genes identiﬁed byArray-Express proﬁling of teratoma RNA obtained from 5 tumors per
genotype. Genes with log2 fold changes N1, adjusted p-values b0.05 are labeled in color. (B) Overview of TiGER analysis of upregulated genes in Evi-GOF tumors. (C) List of upregulated
genes in Evi-GOF teratomas related to muscle differentitaion. (D) Panther analysis of downregulated genes was performed to identify changes in signaling pathways. (E) Expression
proﬁling of downregulated genes obtained by Array-Express analysis (n = 5). Values are normalized to control teratomas. (F) qPCR analysis of indicated genes normalized to control
tumors (control n= 25; Evi-GOF n= 27). Data represents mean ± SEM of 7 experiments. (G) Teratoma section stained with an antibody against MHC II.
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breast cancer studies (data not shown) suggesting a comprehensive
role of Wnt secretion in cancer immune regulation.
The present study was based on a novel mouse teratomamodel. Ac-
cordingly, we analyzed Evi expression in a human Korkola Seminoma
tumor data set, which includes different germ cell tumor classes (em-
bryonal carcinoma, mixed germ cell tumor, seminoma, teratoma, yolk
sack tumor; TCGA, Oncomine) (Fig. S3B). Eviwas upregulated in terato-
mas (fold change 3.579, p-value 3.55E-8) suggesting that teratomas re-
ﬂect another tumor entity with high Wnt importance. Further studies
are necessary to decipher a potential role of Evi in human teratoma im-
mune cell recruitment.3. Discussion
ESCs have the potential to differentiate in all types of cells. In vivo ap-
plication of undifferentiated ESCs leads to teratoma formation (Dressel
et al., 2008; Song et al., 2015). A recent screening study identiﬁed an in-
volvement of Wnt signaling in the transition from benign to malignant
teratocarcinoma growth (Liu et al., 2012). Moreover, upregulated Evi
expression was found in human teratomas supporting the hypothesis
that Evi may contribute to germ cell tumor progression. The Evi-trans-
genic ESC line reported in this study provides a novel research tool to
study teratoma formation. Evi-GOF teratomas showed enhanced
tumor growth demonstrating a tumor-promoting role of Evi in ESCs.
Fig. 4. Evi-GOF teratomas recruit fewer T and B cells. (A) FACS-based analysis of dissociated teratomas of Evi-GOF and control ESCs injected in 129P2/OlaHsd mice after 27 days of
transplantation. Cells were gated according to the indicated markers. (control, n = 7; Evi-GOF, n = 9). (B) Teratoma weight of Evi-GOF and control ESCs injected in Nod/SCID mice
(harvest after 27 days) (n = 15). (C) FACS-based analysis of CD45+ cells in Evi-GOF and control tumors injected in Nod/SCID mice after 27 days of transplantation. (n = 15). (D)
FACS-based analysis of CD4+ and CD8+ leukocytes of Evi-GOF and control tumors (control, n = 7; Evi-GOF, n = 6). (E) FACS-based analysis of CD4+ or CD8+ populations against
CD44 and CD26L expression (control, n = 24; Evi-GOF, n = 25). (F) FACS-based analysis of CD4+ cells against CD25 and FoxP3 (control, n = 21; Evi-GOF, n = 17). (G) FACS-based
analysis of CD4+ cells against IL17 (control, n = 11; Evi-GOF, n = 13). (H) qPCR analysis of indicated genes normalized to control tumors (control n = 17; Evi-GOF n = 22).
Representative FACS plots were shown on the right. Data represents representative analysis (A, C) and mean ± SD of 2–4 experiments (D–G).
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tumor cells had shown that loss of Evi resulted in inhibition of
tumor growth after xenotransplantation (Augustin et al., 2012;
Voloshanenko et al., 2013).Thehost immune response has been identiﬁed as a critical regulator of
tumor development and progression (Dunn et al., 2004; Fridman et al.,
2013; Hadrup et al., 2013). Several types of immune cells participate in
immunosurveillance by direct killing or production of cytokines. Our
613I. Augustin et al. / Stem Cell Research 17 (2016) 607–615expression proﬁling experiments revealed that the majority of genes re-
lated to immunity and defense were signiﬁcantly downregulated in Evi-
GOF teratomas. Accordingly, less CD45+ leukocytes had inﬁltrated Evi-
GOF teratomas. Most notably, we observed a 50% reduction of CD3+ T
cells in Evi-GOF teratomas. Low densities of both CD8+ cytotoxic T cells
and CD45RO+ memory T cells are associated with poor clinical outcome
(Fridman et al., 2013; Becht et al., 2014; Hadrup et al., 2013). The results
of our teratoma experiments support a model whereby highWnt activity
facilitated the escape from the anti-tumor immune control by T cell exclu-
sion. Recent results on Wnt/β-catenin signaling in melanoma have re-
vealed a correlation of canonical Wnt signaling with lack of T-cell
inﬁltration inmousemodels aswell as in humanpatient biopsies suggest-
ing a similar role of Wnt signaling in different types of tumors (Spranger
et al., 2015). Our analysis revealed no overt changes in T cell activation or
effector differentiation, indicating that excessive Wnt signaling impairs T
cell recruitment and/or tumor inﬁltration, rather than intratumoral T cell
activation. Alternatively, the moderate Evi overexpression in ESCs via the
Rosa26 promoter was insufﬁcient to challenge the balance of these T cell
subsets. Regardless of the exactmechanism, elevatedWnt levels promote
increased tumor growth and this effect is mediated through attenuated
immune surveillance. The role of Wnt signaling in mature T cell differen-
tiation is still controversially discussed. Recent publications using phar-
macological or genetic approaches support a role for β-catenin as well
as the β-catenin downstream transcription factor TCF-1 (transcription
factor 7) in memory T cell development (Gattinoni et al., 2009; Zhao et
al., 2010). Whereas other reports showed that expression of stabilized
or deleted β-catenin was dispensable in functional memory T cell differ-
entiation (Prlic and Bevan, 2011; Driessens et al., 2010). It is of note that
TCF-1 can be activated independently ofβ-catenin cooperation and there-
fore does not reﬂect in all cases exclusiveWnt response (Grumolato et al.,
2013; Sprowl andWaterman, 2013). Similarly, studies addressingWnt/β-
catenin signaling in Treg and Th17 function showed on the one hand that
stable β-catenin expression in Tregs supports Treg survival and immune
response (Ding et al., 2008), whereas TCF-1 deﬁcient mutants revealed
stronger suppressive ability of (van Loosdregt et al., 2013). Our teratoma
analysis showed an increase in CD4+CD25+FoxP3+ Tregs population in
Evi-GOF tumors indicating that enhanced Wnt secretion supports Treg
availability. Further experimental analyses will be necessary to clarify
whether this phenotype correlates with β-catenin or β-catenin-indepen-
dent Wnt signaling in T cell populations. Tregs suppress inﬂammatory
mechanisms and thereby attenuate inﬂammation-associated tumor pro-
gression. Otherwise regulatory T cells also inhibit anti-tumor T cell re-
sponses, thereby supporting cancer escape from immune surveillance.
These different functions are probably driven by different Treg subsets,
which might depend on the cancer type and mutation status. (Blatner
et al., 2012; Keerthivasan et al., 2014). Recent reports showed that active
Wnt/β-catenin signaling in Tregs correlates with promotion of colon can-
cer (Keerthivasan et al., 2014). Further studies are necessary to address
this issue in otherWnt-related cancer settings. Moreover, several re-
ports exist, which delineate a role of Wnt signaling in Th17 differen-
tiation during T cell development and mature T cell differentiation
(Ma et al., 2011; Dai et al., 2016; Muranski et al., 2011). Our results
showed an increase in IL17 producing CD4+ T cells in Evi-GOF tera-
tomas indicating that enhanced Wnt secretion is involved in elevat-
ed Th17 response. The supportive or inhibitory role of Th17 in
malignancy is still a matter of debate suggesting that Th17 cells
play a dynamic role in cancer immunity depending on the type of in-
ﬂammatory response and cancer (Martin et al. 2012; Wang et al.,
2009; Iida et al., 2011). Recent reports showed that constitutive acti-
vation of β-catenin promotes chromatin accessibility and target gene
expression for Th17 commitment, which sustained pathogenic in-
ﬂammation and predispose to cancer (Keerthivasan et al., 2014).
Our phenotypical analyses tend towards the same direction. Never-
theless additional studies are necessary to enroll a more detailed leu-
kocyte population analysis including expression pattern of target
genes and cytokines as well as Wnt signal activity.Previous studies have focused on the analysis of tumor inﬁltrating T
cells. In turn, much less is known about the role of B cells in modulating
the immune response to solid tumors (Nelson et al., 2010). It has been
shown for melanoma and several other types of tumors that B cell den-
sity correlates with T cell density indicating that B cells support the an-
titumor immune response (Zirakzadeh et al., 2013). Accordingly, our
study also revealed a concomitant reduction of tumor-inﬁltrating T
and B cells.
In conclusion, the identiﬁcation of Wnt secretion as a regulator of
teratoma growth and immune cell inﬁltration may have profound im-
pact for the molecular understanding of tumor - immune cell crosstalk
with possible translational relevance. Future work will have to unravel
the underlying signaling mechanisms regulating the escape from the
anti-tumor immune response in order to contribute to the further ad-
vancement of cancer immunotherapies.
4. Material and methods
4.1. Cell culture, cell lines, constructs, generation of stable ESC
Evi-GOF ESCs were generated and maintained as previously de-
scribed (Augustin et al., 2012) (genetic background: 129P2/OlaHsd). 6
independent lines were generated. At least two lines per genotype
were investigated to exclude clone-speciﬁc artifacts. Brieﬂy, ESCs were
cultured on mitomycin C inactivated feeder cells (MEFs) in LIF supple-
mented ESC medium (DMEM high glucose (Gibco) supplemented
with 15% FCS (PAN Biotech), 1% Penicillin / Streptomycin (Invitrogen),
2 mM Glutamine (Invitrogen), 100 μM β-mercaptoethanol (Sigma),
1 mM MEM-sodium pyruvate (Invitrogen), 1% non-essential amino
acids (Invitrogen), and 1000 U/ml Leukemia Inhibitory factor (LIF,
Millipore)) (Lin and Talbot, 2011). ESCs were passaged on gelatine-
coated plates to deplete MEFs and used for experiments after 3–5 pas-
sages on gelatine-coated plates. ESCs were cultured at 37 °C, 5% CO2
and passaged 1:3 every 2–3 days.
4.2. Cell viability
To assess cell viability, 1000 cells were plated in 10 replicates on gel-
atine-coated 384-well plates in LIF containingmediumand viabilitywas
measured at indicated time points using CellTiter-Glo (Promega) ac-
cording to the manufacturer's protocol.
4.3. Animal experiments
Viable ESCs (3× 106 cells in 100 μl PBS)were injected into the dorsal
ﬂank of 129P2/OlaHsd or Nod/SCID mice (age of 6–10 weeks). Terato-
mas were isolated 27 days after transplantation. For in vivo analysis,
mice were injected i.p. with EdU (20 μg/g mouse) 2 h before sacriﬁce.
Animal welfare and experimental procedures were performed in accor-
dance to German animal protection law and were approved by the
Regierungspräsidium Karlsruhe, Germany (AZ 35–9185.81/230/11).
4.4. Immunohistochemistry
Following deparafﬁnation, antigen retrieval was performed by
heating sections at 98 °C for 10 min in 10 mM citrate buffer (pH 6.0).
To block endogenous peroxidase, sections were treated with 3% H2O2
for 20 min. After blocking with avidin/biotin blocking (Dako) solution
at room temperature for 1 h. Sectionswere incubatedwith CD3 primary
antibodies in blocking solution overnight at 4 °C. Following washings
with PBS, the slides were incubated with HRP-labeled secondary anti-
body for 3 h at room temperature. Incubation with Avidin/Biotin com-
plex (Dako) was done for 30 min at room temperature, followed by
incubation with diaminobenzidine substrate until brown color ap-
peared. Counterstaining was performed with hematoxylin. Sections
614 I. Augustin et al. / Stem Cell Research 17 (2016) 607–615were mounted in Histoﬂuid (Engelbrecht), and photographed using a
Zeiss Axioskop 40 microscope.
4.5. FACS analysis
Teratomas were mechanically minced into small pieces using scal-
pels, followed by a digestion step for 2 h at 37 °C in collagenaseD at con-
centration of 2 mg/ml in RPMI medium supplemented by 10% FCS,
Penicillin/Streptomycin (Invitrogen) and 2mMGlutamine (Invitrogen).
Gentle pipettingwas performed duringdigestion. Cell suspensionswere
ﬁltered through a 70 μm nylon ﬁlter mesh (BD), washed in PBS once,
counted and processed for antibody staining and FACS analysis. For
IL17 staining cells were stimulated with cell stimulation cocktail plus
transport inhibitors (ebioscience) for 4 h at 37 °C. FoxP3 stainings
were performed according to FoxP3/Transcription Staining Buffer Set
(ebioscience). Single cell suspensions from teratomas or cultured cells
were stained with antibodies diluted in PBS containing 5% FCS for
45min at 4 °C. For intracellular labeling, cells were permeabilized either
with 0.2% Triton X100/PBS for 5min before incubation with conjugated
primary antibodies or according to FoxP3/Transcription Staining Buffer
Set. Secondary antibody staining was performed for non-ﬂuorescent
conjugated primary antibody. After staining, cells were ﬁxed with 2%
PFA for 10 min, washed and subsequently processed for FACS analysis.
Proliferation and apoptosis assays were performed using EdU-Click iT
reagent (Invitrogen) and PE Active Caspase-3 Apoptosis Kit (BD
pharmingen), according to themanufacturer's instruction. Fluorescence
data were obtained with a FACS LSRII (BD) with FACS Diva software.
Data were subsequently analyzed using Flow Jo 10.1 software. Antibod-
ies are listed in Table S1, 2.
4.6. Western blot analysis
Cell pellets were lysed in urea buffer containing 8 M urea in PBS. Ly-
sates were incubated on ice for 30 min and centrifuged at 3000 g for
15 min at 4 °C. Supernatants were collected and protein concentrations
were determined by BCA (Perbio, Thermo Scientiﬁc) according to the
manufacturer's instructions. Proteins (15 μg) were supplemented with
5× Laemmli buffer and heated for 10min at 80 °C. Cell lysateswere sep-
arated on 4–12% NuPage gradient gels Bis-Tris (Life Technologies) and
transferred to PVDF membranes (Millipore, Merck Biosciences). In
order to enrich Wnt proteins in cell culture supernatants medium was
centrifuged at 15,000 g for 10 min to get rid of debris. Triton X100 (1%
ﬁnal) was added to the medium followed by addition of 50 μl blue se-
pharose beads (GE Healthcare) per 10 ml medium. Mix was incubated
overnight at 4 °C. After washing the beads three times (150 mm KCL,
50 mM Tris-Cl, 1% Triton X100) the beads were resuspended in 2×
Laemmli buffer and heated for 5min at 96 °C. Supernatants were loaded
on 4–12% NuPage gradient gels Bis-Tris (Life Technologies) and trans-
ferred to PVDF membranes (Millipore, Merck Biosciences). Membranes
were blocked in 5% non-fat dry milk/PBS incubated overnight at 4 °C
with primary antibodies. Blots were then incubatedwith corresponding
HRP–conjugated secondary antibodies (Sigma-Aldrich). Antibodies are
listed in Table S1, 2.
4.7. RNA, RT-PCR and expression proﬁling
Total RNA was extracted from ESCs and teratomas using RNAeasy
extraction kit (Qiagen) according to themanufacturer's instructions. Re-
verse transcription and quantitative PCR was performed with 25 ng
cDNA and LightCycler 480 ProbesMaster as described (Roche) (Primers
were listed in Table S2). Relative mRNA expression was calculated as a
fold change versus control. Teratomas were harvested 27 days after
ESC injection and pulverized thoroughly in a mortar cooled with liquid
nitrogen for further extraction of RNA.
Total RNAwas isolated from each of the 10 teratoma samples using
RNAeasy Kit (Qiagen) and labeled cRNA were prepared according toIllumina TotalPrep-RNA ampliﬁcation protocol (P/N IL1791M, Life
Technologies). 1.5 μg cRNA were hybridized for 17 h at 58 °C on
Illumina BeadChip Sentrix array (mouse WG-6 v2.0) according to
Standard Illumina Hybridization protocol (#11322355). Gene expres-
sion microarrays were scanned using the Illumina iScan-Scanner ac-
cording to Standard Illumina Scanning protocol, using BeadStudio
software (v3.2). The limma package (v3.2.1), part of the
Bioconductor/R package, was employed to test for differential expres-
sion (Wettenhall and Smyth, 2004). This test assumes a linear model
for gene expression levels. The differential expression test between
Evi-GOF and control teratoma samples is based on the null hypothesis
that the expression values of a gene in the samples come from the
same distribution and results in p-values for each gene. A simple de-
sign matrix was created to ﬁt a linear model to each gene expression
value. An empirical Bayes method was used to moderate standard er-
rors and estimate log fold change from the data, and a moderated t-
statistic was used to assess differential expression. Genes which had
an adjusted (Benjamini–Hochberg} p-value b 0.05 and absolute
value of log2 fold change greater than 1were regarded as differentially
expressed, and used for further PANTHER (Mi et al., 2005) (http://
www.pantherdb.org/) and TiGER (Liu et al., 2008) (http://bioinfo.
wilmer.jhu.edu/tiger/) analysis. Analysis of the correlation of Evi and
leukocytemarkerswas performedwith R2: Genomics Analysis and Vi-
sualization Platform. http://hgserver1.amc.nl/cgi-bin/r2/main.cgi?
&species=hs. Evi expression in germ cell tumors was analyzed in
Oncomine, www.oncomine.com.4.8. Statistical analysis
Unless otherwise indicated, data are expressed asmean±SD. Statis-
tical signiﬁcancewas calculated by a two-tailed Student's t-testwith un-
equal variance. A p-value of b0.05 was considered statistically
signiﬁcant andmarked in comparisons by asterisks. One asterisks repre-
sent p-values of b0.05. Two asterisks mark p-values of b0.01.4.9. Accession numbers
Expression proﬁling data is submitted to ArrayExpress E-MTAB-
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